MCS to run comms for ImClone cancer treatment Erbitux

BEDMINSTER, NJ: ImClone Systems and Bristol-Myers Squibb have retained MCS, a healthcare-focused PR firm, to handle communications for their investigational cancer drug Erbitux.

BEDMINSTER, NJ: ImClone Systems and Bristol-Myers Squibb have retained MCS, a healthcare-focused PR firm, to handle communications for their investigational cancer drug Erbitux.

The agency would not comment on the details or duration of the account, but said both companies were clients prior to last week's American Society of Clinical Oncology meeting. At the event, scientists said Erbitux had positive results for colon-cancer patients in clinical trials.

The revelatory study was sponsored by the holder of the European rights of Erbitux, Merck KGaA (not affiliated with Merck in the US), but MCS said it is not working with that company.

Abernathy MacGregor is ImClone's AOR. In October of last year, ImClone retained the agency after CEO Sam Waksal was accused of insider trading. Two months later, the FDA released a disappointing report about Erbitux's potential - the day after Martha Stewart sold her shares of ImClone stock.

Stewart resigned as chairman and CEO of Martha Stewart Living Omnimedia after she

was indicted last week.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in